Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
CMR Surgical kicks off Versius Plus robot’s US commercial launch
(2h)
Philips AI cath lab copilot nets FDA clearance
(4h)
Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses
(4h)
OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline
(4h)
Wave crashes after obesity trial tracks 1% dip in body weight over 6 months
(5h)
BioPharma Dive
Merck’s deal for Terns sparks debate over a possible biotech bidding war
(2h)
FDA clears Denali drug in ‘clear step’ for rare disease biotechs
(3h)
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
(4h)
Maze tumbles on positive data for kidney disease drug
(23h)
Beam posts positive data on base editing treatment for AATD
(1d)
Endpoints News
Biopharma industry pushes back on FDA's 'America First' user fee proposals
(1h)
Recordati says it's received a $12B+ takeover bid
(1h)
UCB picks Georgia for $2B biologics site; AbbVie exec visits China
(2h)
New tech, familiar problems
(2h)
Wave crashes on obesity disappointment
(3h)
BioSpace
Wave Stock Cut in Half on Underwhelming Higher Dose Obesity Data
(4h)
Beam’s Base Editor Advances to Pivotal Development on Back of ‘Impressive’ AATD Data
(6h)
Denali Delivers ‘Welcome Positive’ for Rare Disease Space With FDA's Hunter Syndrome Nod
(7h)
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise
(7h)
Beyond Buzzwords in Longevity Investing
(10h)
STAT News
Eli Lilly’s deal man, Allogene’s off-the-shelf CAR-T, and Merck’s Terns buy
(1h)
Denali Therapeutics, Corcept Therapeutics win FDA approvals
(2h)
Health influencers talk social media and mental health
(3h)
A surprise opening for health care reforms
(4h)
White House misses deadline to nominate new CDC director
(4h)
BioPharma Trend
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(1h)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(21h)
Bioptimus Launches Multimodal Tissue Atlas Across Three Continents
(1d)
Merck Signs $20M Deal With Quotient to Find IBD Targets Using Somatic Genomics
(2d)
insitro and Bristol Myers Squibb Add New AI-Found Targets in ALS Research
(3d)
Drug Channels
Reflections and Photos from the Drug Channels Leadership Forum 2026
(1d)
NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers
(2d)
Medical Benefit Maximizers Are Emerging as a Critical Market Force: What Manufacturers Need to Understand
(6d)
The Top 15 U.S. Pharmacies of 2025: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies
(1w)
Reshaping Patient Affordability: The Power of Expertise and Agility
(2w)
European Biotechnology Magazine
TenBoron lands €7.6m EU grant for precision radiotherapy trials in hard-to-treat cancers
(2h)
Immutrin secures £65m Series A for amyloid-removing heart therapy
(1d)
Organoids: new Roche research centre in Basel will focus on alternative model systems
(1d)
Sanofi inks up-to-$1.2bn autoimmune T-cell engager deal with Kali Therapeutics
(2d)
Mitigating regulatory risk with holistic CMC strategies
(2d)
Drug Hunter
February 2026 Patent Highlights
(3h)
ACS Spring 2026 First Time Disclosures
(20h)
TL1A Inhibition in IBD: Deamplifying Biology for Clinical Proof-of-Concept
(2d)
QPX7728
(3d)
Dose as the Ultimate MPO Endpoint
(5d)
Labiotech.EU
GSK’s two-speed strategy: broad sourcing and selective bets
(1d)
Seven T cell engager companies you should know about
(2d)
The six biotech companies in Portugal you should know about in 2026
(3d)
After the drought, biotech IPO activity begins to pick up in 2026
(6d)
How Leyden Labs is revolutionizing flu protection with its intranasal antibody spray
(6d)
Bio IT World
The Value of Prediction, and Cost of Success, in Drug Hunting
(13h)
Follow the Money: Brain-Computer Retinal Implant, Expansion of Alzheimer’s Platform, Migraine Therapies
(1d)
Verily, Samsung Collaborate, Improving AI Trustworthiness, FDA Approval for PathAI
(2d)
PerturbAI Launches with CRISPR Atlas
(5d)
piRNAs Emerge as a New Frontier in Longevity
(1w)
GEN News
From Variability to Reliability: A New IgG4 Reference Standard for Consistent Characterization
(5h)
Georgia Chosen as the Location for UCB’s New U.S. Biologics Manufacturing Facility
(6h)
Merck Bolsters Cancer Pipeline with $6.7B Terns Buyout
(22h)
Leveraging the Full Potential of Regenerative Medicine Requires a Proactive Approach
(22h)
Parasites Prompt Gut-Brain Communication to Trigger Appetite Loss
(22h)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(5d)
Understanding High-Risk Essential Thrombocythemia
(5d)
Son’s Decision to Donate Gave His Father a Second Chance
(5d)
Functional Precision Medicine Advances Brain Tumor Care
(6d)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(6d)
Contract Pharma
Hoth Therapeutics Launches OpenClaw AI for Accelerating Drug Discovery
(1h)
Lifecore Biomedical Inks Two New Agreements with Existing US Customer
(3h)
Piramal Pharma Solutions Procures Korsch X3 Tablet Press at Morpeth Facility
(22h)
Incyte Appoints Three to Executive Leadership Positions
(23h)
Sygnature Discovery Taps Susanne Back to Lead In Vivo Pharmacology Team
(1d)
Pharma Times
Laigo Bio completes final close of €17m seed financing round
(9h)
Axplora announces expansion as newest part of $60m API investment programme
(1d)
DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
(2d)
Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
(3d)
Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
(1w)
Medcity News
Frozen Does Not Mean Stable: Rethinking Cryopreservation in Cell and Gene Therapy Manufacturing
(4h)
DPC Is Scaling — The Financing Architecture Isn’t Ready
(5h)
Personalized Rehab Solution: Supporting Patients With Work Responsibilities
(5h)
Could There Be a ‘Soft Opening’ of H.R. 1 Medicaid Changes?
(16h)
Adonis Scores $40M for AI Platform Aiming to Boost Hospital Revenue
(17h)
Chemical & Engineering News
Universities forge a bumpy new path on indirect research costs
(38m)
New drug candidates debut in Atlanta
(38m)
Supercapacitors built from bourbon waste
(2h)
Glyphosate could be boosting spread of multidrug-resistant bacteria
(5h)
How fish scales help reconstruct historical PFAS trends
(22h)
The Pharma Letter
Wave hits the rocks on confounding obesity trial
(1h)
Second positive Phase III results for Kodiak’s Zenkuda
(2h)
Late-stage pipeline to transform progressive pulmonary fibrosis treatment landscape
(2h)
Global R&D Trends 2026
(3h)
BRIEF—Lonza launches new development lab in Singapore
(4h)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(1w)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(1w)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(1w)
Treating Triple Negative Breast Cancer in the Frontline Setting
(1w)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(1w)
MedWatch
Novo Nordisk chairman: Cost-cutting was the most challenging decision in 2025
(4h)
Gubra re-elects board of directors
(4h)
Lundbeck Foundation reshuffles its board of directors
(4h)
Sweden bans Novo Nordisk's advertising for Wegovy following criticism
(5h)
BioPorto remains committed to reducing its operating deficit
(6h)
In The Pipeline
Fentanyl's Membrane Behavior
(22h)
Set Phasers to "Kill". No, Not Those Phasers.
(1d)
AI-Predicting Compound Affinity. We Aren't There Yet.
(2d)
From Gut Bacteria Up to the Brain
(6d)
Beneficial Effects From the Liver to the Brain
(1w)
Pharmaphorum
Wave's stock wavers on obesity drug data
(1h)
AI predicts liver cancer risk with "high accuracy"
(6h)
Corcept gets FDA OK for first-in-class ovarian cancer drug
(8h)
FDA clears Denali's 'game-changer' Hunter syndrome drug
(9h)
Anavex sinks after pulling Alzheimer's filing in EU
(23h)
Drug Discovery Weekly
Global collaboration aims to create safer cancer therapeutics
(4h)
DDW Highlights: 26 March 2026
(7h)
Obesity could be treated without suppressing appetite
(8h)
Whitepaper: Secure your place in the IND race
(9h)
Just – Evotec Biologics enters $10m agreement with BARDA
(9h)
HIT Consultant
Beyond the AI Arms Race: Why Collaborative Intelligence Is the Only Path Forward for Utilization Management
(1d)
The RCM Trap: Why Cityblock Health is Pivoting AI Investment Toward Medicaid Care
(1d)
The C-Suite Squeeze: Why Hospital IT Budgets Are Shrinking While AI Spending Soars
(2d)
Hopper OS Acquires Healthcare Informatics Company Efferent to Expand Cloud PACS and Interoperability
(2d)
TruBridge and Artesia General Hospital Integrate Microsoft Dragon Copilot into EHR
(2d)
Insights: Pink Sheet
Quotable: Top Experts On Policy Hot Topics
(4h)
Iran War: Fuel Woes Exacerbate Fragility Of Europe’s Medicines Distribution System
(5h)
India Tightens Oversight Of GLP-1 Supply Chain Amid Concerns Of ‘On-Demand’ Availability
(10h)
Denali’s Avlayah Offers Broader Treatment Of Hunter Syndrome, Evidence Of US FDA Flexibility
(19h)
US FDA Allergenics Staff Sees Single-Trial ‘Default’ As Helpful
(22h)
BioXconomy
How the Digital Medicine Society is advancing clinical trials with digital innovation
(2h)
DiMe CEO on how digital medicine is set to redefine clinical trials
(2h)
Merck bolsters oncology portfolio with $6.7bn acquisition of Terns
(7h)
PhaseV debuts AI offering to automate clinical trials
(1d)
Pfizer’s trispecific antibody shows promise in treating eczema
(1d)
BioCentury
Science Spotlight: AI studies link preserved thymic function to longer life
(18h)
With $6.7B buy, Merck sees ‘best-in-class’ blockbuster in Terns’ CML therapy
(19h)
Denali approval revives surrogate-endpoint path in neuronal MPS
(19h)
MHRA’s Tallon on the tall order of boosting the U.K. as a destination for clinical trials
(20h)
AL-S Pharma tests how far SOD1 biology extends into sporadic ALS
(1d)
SCRIP
How The Kelun-Merck Pact Shaped Future Of China Dealmaking
(2h)
Anavex Not Giving Up On Alzheimer’s Drug After EU Rejection
(4h)
Executives On The Move: Alphamab Oncology Gets A New CFO From AstraZeneca
(7h)
Biogen Added To Alteogen’s Long List Of Partners
(14h)
Denali’s Avlayah Offers Broader Treatment Of Hunter Syndrome
(21h)